AtonRa Partners Decreases Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

AtonRa Partners lessened its stake in Bicycle Therapeutics plc (NASDAQ:BCYC) by 9.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,435 shares of the company’s stock after selling 1,153 shares during the quarter. AtonRa Partners’ holdings in Bicycle Therapeutics were worth $189,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. BluePath Capital Management LLC acquired a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $31,000. China Universal Asset Management Co. Ltd. increased its stake in Bicycle Therapeutics by 489.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,001 shares of the company’s stock worth $72,000 after buying an additional 3,322 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Bicycle Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after buying an additional 1,706 shares in the last quarter. Woodstock Corp raised its holdings in shares of Bicycle Therapeutics by 4.5% during the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock valued at $388,000 after acquiring an additional 926 shares during the last quarter. Finally, Maven Securities LTD purchased a new position in shares of Bicycle Therapeutics in the third quarter valued at approximately $452,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on BCYC shares. Canaccord Genuity Group restated a “buy” rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, February 21st. HC Wainwright dropped their price target on Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday, February 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $46.86.

Bicycle Therapeutics Trading Up 4.0 %

Shares of NASDAQ BCYC traded up $0.94 during mid-day trading on Tuesday, reaching $24.35. 80,178 shares of the company’s stock were exchanged, compared to its average volume of 368,875. The company’s 50-day moving average is $23.98 and its 200-day moving average is $19.35. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.08 and a current ratio of 8.08. Bicycle Therapeutics plc has a 52-week low of $12.54 and a 52-week high of $28.91.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, February 20th. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.07. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $11.68 million. As a group, analysts forecast that Bicycle Therapeutics plc will post -5.2 earnings per share for the current year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total value of $75,191.98. Following the completion of the sale, the chief executive officer now owns 387,270 shares in the company, valued at approximately $9,220,898.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 5,312 shares of company stock worth $126,139. 10.20% of the stock is currently owned by insiders.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.